UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of July, 2009
Commission File Number 000-22286
Taro Pharmaceutical Industries Ltd.
(Translation of registrant's name into English)
14 Hakitor Street, Haifa Bay 26110, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F |X| Form 40-F |_|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes |_| No |X|
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_____.
2
On July 20, 2009, the Company's Board of Directors received a letter
from Franklin Templeton Investments concerning the status of the audit of its
financial statements by the Company's independent auditors. Franklin Templeton
Investments has expressed concern over the delay in issuing the Company's
audited financial statements for 2006-2008 and requested that a shareholders
meeting be convened at which the auditors be present and answer the
shareholders' questions.
The Company intends to call an extraordinary general meeting of
shareholders shortly, at which the Company looks forward to updating its
shareholders on the progress of the audits.
SAFE HARBOR STATEMENT
Certain statements in this 6-K filing are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements include, but are not limited to, statements that do not describe
historical facts and statements that refer or relate to events or circumstances
the Company "estimates," "believes," or "expects" to happen, "should" happen, or
similar language, statements with respect to the Company's financial
performance, availability of financial information and estimates of financial
results and financial information for 2006, 2007 and 2008. Although Taro
Pharmaceutical Industries Ltd. believes the expectations reflected in such
forward-looking statements to be based on reasonable assumptions, it can give no
assurances that its expectations will be attained. Factors that could cause
actual results to differ include the possible unavailability of financial
information, delay in completion of the audits of 2006, 2007 and/or 2008,
actions of the Company's lenders, creditors and Sun Pharmaceutical Industries
Ltd. ("Sun"), including but not limited to the outcome of litigation with Sun,
general domestic and international economic conditions, industry and market
conditions, changes in the Company's financial position, litigation brought by
any party in any court in Israel, the United States, or any country in which
Taro operates, regulatory actions and legislative actions in the countries in
which Taro operates, and other risks detailed from time to time in the Company's
SEC reports, including its Annual Reports on Form 20-F. Forward-looking
statements speak only as of the date on which they are made. The Company
undertakes no obligations to update, change or revise any forward-looking
statement, whether as a result of new information, additional or subsequent
developments or otherwise.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: July 28, 2009
TARO PHARMACEUTICAL INDUSTRIES LTD.
By: /s/ Tal Levitt
--------------
Name: Tal Levitt
Title: Director and Secretary